Skip to main
  1. Stocks
  2. Hinge Health Inc
  3. Forecast
HNGE

HNGE Stock Forecast & Price Target

HNGE Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 60%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Hinge Health is favored because its core MSK business remains deeply underpenetrated, with management estimating roughly 88%-90% of addressable U.S. lives still lack digital MSK access, while contracted clients rose 28% Y/Y to 3,270 and LTM billings grew 54% to $960 million. Strong selling-season momentum, over 5 million verbally committed net new lives, and improved yield to an expected 4.6% support a framework for 20%-25% 2027 billings growth and mid-to-high-20% revenue growth, with management also expecting 100-200 bps of operating-margin expansion. The outlook is further strengthened by emerging growth levers in Migraine, GI, SMB, and multi-product adoption, alongside high gross margins near 88% and operating leverage that can sustain profitability even as care-team capacity expands.

Bears say

Hinge Health is likely to face margin pressure as gross margin moves from approximately 88% in 3Q to 86%-87% in 4Q26 and potentially stays there in 1Q27, reflecting care-team hiring needed to reduce an already elevated ratio of more than 2,000 paid members per care-team member toward 1,800. This hiring may limit operating leverage and delay any improvement in adjusted EBITDA margin, while pricing pressure and the risk that AI-driven efficiencies fail to reduce human intervention could further compress profitability as the company scales. The negative outlook is also driven by a weaker demand backdrop in 2H26, slower FY27 growth risk, and customer concentration, as the top three partners account for more than 40% of revenue year-to-date 2025.

HNGE has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 60% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hinge Health Inc and is not a guaranteed prediction by Public.com or investment advice.

HNGE Analyst Forecast & Price Prediction

Get the latest HNGE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HNGE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hinge Health Inc (HNGE) Forecast

Analysts have given HNGE a Buy based on their latest research and market trends.

According to 15 analysts, HNGE has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hinge Health Inc (HNGE)


HNGE Analyst Forecast & Price Prediction

Get the latest HNGE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HNGE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HNGE stock data and trends